Get the latest news, insights, and market updates on VVOS (Vivos Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing and treatment center near Detroit i Dec 16, 2025 - $VVOS
Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company’s CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research Dec 15, 2025 - $VVOS
Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ETLITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today an Nov 19, 2025 - $VVOS
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective d Nov 19, 2025 - $VVOS
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep ApneaLITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), Sep 30, 2025 - $VVOS
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSALITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatmen Sep 17, 2025 - $VVOS
Sleep Apnea Economic Burden in U.S. Exceeds $150B Annually--Vivos' Novel Solution Can Help
Obstructive sleep apnea (OSA) is wreaking havoc on individuals and healthcare systems alike, contributing to hypertension, diabetes, depression, and even stroke, while costing the U.S. economy a staggering $150 billion annually. (1-2) Despite its devastating impact, OSA remains underdiagnosed and undertreated. A recent study found untreated OSA patients incur healthcare costs averaging $19,566 per year, primarily due to inpatient care. (3) Sep 2, 2025 - $VVOS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple